Thursday, September 18, 2025 9/18/2025

Cell-free synthesis of influenza virus-like particles (VLPs) as prototyping platform for vaccine development and variant characterization

Award Number: R03AI176165
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2026

Group Awards By:

View Award Description

Cell-free synthesis of influenza virus-like particles (VLPs) as prototyping platform for vaccine development and variant characterization - SUMMARY The absence of prophylactic and low-cost influenza vaccines along with slow production rate makes us unprepared for the next pandemic outbreak worldwide. Recombinant virus-like particles (VLPs) vaccines provide us with unique opportunities to address these difficulties, but their recombinant synthesis strategies are limited to cell culture production, which has its challenges such as limited throughput and architectural heterogeneity of the obtained products. In this project, we aim to combine wheat germ cell-free protein expression platform with active microsomes of different origins (including human) to synthesize glycosylated influenza virus-like particles (VLPs). These particles will further undergo detailed morphological and compositional examination using electron microscopy and native mass spectrometry to understand the architecture of obtained products and understand the mechanisms of their assembly and composition variability. High- resolution tomography will be utilized to determine the best VLP candidates with maximal antigen occupancy and thus maximal vaccine efficiency. We hypothesize that this approach will be suitable for a stable and streamlined generation of Influenza VLPs and will offer much more flexibility and control over their architectural heterogeneity and eventually serve as a rapid prototyping platform for influenza vaccine development. The current project will also inform us about the utility of using such approaches for virology and for glycoprotein synthesis in general.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Allergy and Infectious Diseases Research	000	2	5/2/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $92,840 )
2024	2024	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Allergy and Infectious Diseases Research	000	2	3/21/2024	NON-COMPETING CONTINUATION	$92,840
														Subtotal = $92,840

Issue Date FY: 2023 ( Subtotal = $80,715 )
2023	2023	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Allergy and Infectious Diseases Research	000	1	3/27/2023	NEW	$80,715
														Subtotal = $80,715

Grand Total All Awards = $173,555

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cell-free synthesis of influenza virus-like particles (VLPs) as prototyping platform for vaccine development and variant characterization

Award Number: R03AI176165

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer